Table 2 MSCs therapy for senescence-related diseases in clinical trials
From: Application of mesenchymal stem cells for anti-senescence and clinical challenges
Senescence-related disease | Â | Stem cells | Trial size | Treatment measures | Follow-up period | Results |
|---|---|---|---|---|---|---|
Senescence | Frail elderly patients | Allo-hMSCs | 30 | Intravenous injection of allo-hMSCs | 12Â months | Two frailty syndrome measures were found to improve, and it showed reduce frailty, improve cardiovascular function, reduce inflammation, prolong life span and improve quality of life in frail patients, which has great safety [144] |
Osteoporosis | OVCF | WJ-MSCs | 20 | Transplantation of WJ-MSCs and teriparatide | 12Â months | Promote bone healing, possible MSC-related complications such as pulmonary embolism and tumor formation occurred [156] |
CVDs | AMI | BMSCs | 45 | BMSCs were administered into infarct-related artery | 12Â months | Slight improvement of myocardial perfusion in the BMSCs group [233] |
| Â | Severe ischemic heart failure | MSCs | 55 | Intra-myocardial injections of MSCs | 6Â months | Improved myocardial function and no side effects were identified [234] |
| Â | Non-ischemic cardiomyopathy | Allogeneic MSCs | 22 | Intravenous allogeneic MSCs | 90Â days | Therapy was safe, improved health status and functional capacity [235] |
| Â | Heart failure | UC-MSCs | 30 | Intravenous infusion of UC-MSCs | 12Â months | Improvements in left ventricular function, functional status, and quality of life [236] |
Neurodegenerative diseases | AD | MSCs | 9 | Repeated intracerebroventricular injections of MSCs | 36Â months | While showing a certain therapeutic effect, patient had an adverse symptom of fever [179] |
| Â | ALS | BMSCs | 26 | BMSCs via lumbar puncture into the cerebrospinal fluid | 18Â months | 30% of the patients experienced a mild-to-moderate headache, no suspected serious adverse reactions (SUSAR) were observed, slow down progression of ALS [181] |
|  | PD | BMSCs | 7 | The BMSCs were transplanted into the sublateral ventricular zone by stereotaxic surgery | 10–36 months | No serious adverse events occurred but the effectiveness of the treatment was not demonstrated [182] |
POF | Â | UC-MSCs | 14 | Transplantation of UC-MSCs on collagen scaffold | At least 1Â year | Partially improved the activation and growth of follicle and improved fertility [192] |
CKD | Patients with type 2 diabetic nephropathy | BMSCs | 30 | BMSCs infusion | 60Â weeks | Showed low efficacy, no adverse events related to the infusion were noted [208] |
| Â | Â | MSCs | 7 | Intravenous injection | 18Â months | Showed that a single dose infusion of autologous MSCs was safe and well tolerated in patients with CKD [209] |
COPD | Â | Allo-hMSCs | 62 | Intravenous injection | 2Â years | Reduced inflammation and no significant adverse [216] |
| Â | Â | UC-MSCs | 20 | Â | 6Â months | UC-MSC therapy was safe and could improve the lives of patients with moderate-to-severe COPD [218] |